Kyverna Therapeutics (KYTX) Change in Account Payables (2023 - 2026)
Kyverna Therapeutics posted quarterly Change in Account Payables of $6.3 million for Q1 2026, up 65.83% year-on-year from $3.8 million in Q1 2025, and up 803.48% on a QoQ basis from -$892000.0 in Q4 2025.
Kyverna Therapeutics (KYTX) has 4 years of Change in Account Payables data on file, last reported at $6.3 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 65.83% year-over-year to $6.3 million; the trailing twelve-month figure through Mar 2026 stood at -$9000.0 (down 100.62% YoY), and the FY2025 full-year result was -$2.5 million, down 439.67% from the prior year.
- Change in Account Payables for Q1 2026 stood at $6.3 million, up from -$892000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $6.3 million in Q1 2026 and bottomed at -$6.8 million in Q3 2025.
- The 4-year median for Change in Account Payables is $509000.0 (2023), against an average of $661076.9.
- Peak annual rise in Change in Account Payables reached 2821.9% in 2024, while the deepest fall reached 528.78% in 2024.
- A 4-year view of Change in Account Payables shows it stood at $3.0 million in 2023, then plunged by 277.84% to -$5.3 million in 2024, then jumped by 83.16% to -$892000.0 in 2025, then jumped by 803.48% to $6.3 million in 2026.
- The last three Change in Account Payables figures came in at $6.3 million (Q1 2026), -$892000.0 (Q4 2025), and -$6.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Kyverna Therapeutics | 497.98 Mn | 265.03 Mn | - | 6.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.28 Mn |
| Mar 31, 2026 | 6.28 Mn |
| Dec 31, 2025 | -892,000.00 |
| Dec 31, 2025 | -892,000.00 |
| Sep 30, 2025 | -6.80 Mn |
| Sep 30, 2025 | -6.80 Mn |
| Jun 30, 2025 | 1.41 Mn |
| Jun 30, 2025 | 1.41 Mn |
| Mar 31, 2025 | 3.78 Mn |
| Mar 31, 2025 | 3.78 Mn |
| Dec 31, 2024 | -5.30 Mn |
| Dec 31, 2024 | -5.30 Mn |
| Sep 30, 2024 | 5.07 Mn |
| Sep 30, 2024 | 5.07 Mn |
| Jun 30, 2024 | -2.10 Mn |
| Jun 30, 2024 | -2.10 Mn |
| Mar 31, 2024 | 3.07 Mn |
| Mar 31, 2024 | 3.07 Mn |
| Dec 31, 2023 | 2.98 Mn |
| Dec 31, 2023 | 2.98 Mn |
| Sep 30, 2023 | 509,000.00 |
| Sep 30, 2023 | 509,000.00 |
| Jun 30, 2023 | 490,000.00 |
| Jun 30, 2023 | 490,000.00 |
| Mar 31, 2023 | 105,000.00 |
| Mar 31, 2023 | 105,000.00 |